HSP90B1 and colorectal carcinoma: Therefore, on the basis of our findings, we believe that GRP94 might be a novel potential therapeutic target in cetuximab-resistant CRC and that antibody-based targeting of GRP94 might be effective in reducing CRC growth in cetuximab resistance cases.